Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MT10109L (nivobotulinumtoxinA) for lateral canthal lines with or without concurrent glabellar line treatment
2014-005302-38Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lateral canthal rhytides and glabellar furrowing comparing MT10109L with Placebo (2 arms). Primary endpoint: Responder rate for lateral canthal lines. Started Jan 2019; status: completed.
02
Drugs
nivobotulinumtoxinA
03
Conditions
lateral canthal rhytidesglabellar furrowing
Beyond the preview
Go deeper on 2014-005302-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005302-38.